UK psychiatric diagnostics company Psynova Neurotech is among an eight-member consortium which has received a European government grant.
UK-based psychiatric diagnostics company Psynova Neurotech is among an eight-member consortium which has received a grant from the European Commission.
The grant, worth €2.75 million (£2.35 million), is aimed at developing technology that could diagnose mental disorders such as schizophrenia at an early stage.
The consortium consists of four research institutions across Europe, three companies including Psynova Neurotech, and innovation network Pera International which will help manage the three-year project.
Psynova Neurotech was established in 2005 by two Cambridge University scientists, Sabine Bahn and Chris Lowe. It builds on 12 years of research by Bahn identifying so-called “biomarkers” for neuropsychiatric illnesses.
Says Bahn, ‘The biomarker panels represent tools to help general practitioners and psychiatrists in the difficult task of diagnosing and treating patients much sooner, ideally when symptoms are still mild.’
